Patrycja Mensah

Suggest Changes
Learn More
BACKGROUND The reported probability of survival of patients with Hodgkin's disease (HD) following high-dose chemotherapy with autologous stem cell transplantation (HDC/ASCT) is 35-65% at 5 years. The(More)
Autological transplantation of bone marrow as well as hematopoietic and precursor cells obtained from peripheral blood with the use of cell apheresis is a therapy applied in the treatment of(More)
We analysed the treatment outcome of primary refractory HD patients managed with high-dose chemotherapy and haematopoietic cell transplantation. Data of 65 adult patients who underwent HDC/ASCT in(More)
6641 Background: According to current EBMT recommendations 2.0 x 106 CD34 positive cells /kg is regarded as adequate transplant material, capable to reconstitute hematopoiesis after high dose(More)
  • 1